GYKI-47261 dihydrochloride is used as a competitive, orally active, and selective AMPA receptor antagonist with broad-spectrum anticonvulsant and neuroprotective effects; it also serves as a potent inducer of CYP2E1. It demonstrates anti-ischemic effects in a transient focal ischemia model in rats; effectively mitigates oxotremorine-induced tremor in male CD1 mice (ED50 = 16.8 mg/kg, p.o.); and reverses the dopamine-depleting effect of MPTP in male C57 black mice (20 mg/kg, i.p.), restoring striatal dopamine concentrations.